PharmaEngineROCO:4162 79 PEG Ratio is 3.87 as of Jul. 12, 2026, which is 114% above its 10-year median of 1.81. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$115.42 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 94 Biotechnology companies, PharmaEngine ranks worse than 71.28% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for PharmaEngine's PEG Ratio or its related term are showing as below:
ROCO:4162'
s PEG Ratio Range Over the Past 10 Years
Min: 0.17 Med: 1.81 Max: 63.58
Current: 3.87
During the past 13 years, PharmaEngine's highest PEG Ratio was 63.58. The lowest was 0.17. And the median was 1.81.
ROCO:4162's PEG Ratio is ranked worse than 71.28% of 94
companies
in the Biotechnology industry
Industry Median: 1.94
vs ROCO:4162: 3.87
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
PharmaEngine (ROCO:4162) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
PharmaEngine PEG Ratio Related Terms
PharmaEngine PEG Ratio Historical Data
* Premium members only.
The historical data trend for PharmaEngine's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, PharmaEngine's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's PEG Ratio distribution charts can be found below:
* The bar in red indicates where PharmaEngine's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
PharmaEngine (ROCO:4162) has a PEG Ratio of 3.87 as of Jul. 12, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on PharmaEngine and its competitors. This is 114% above median its historical median of 1.81. Over the past decade, PharmaEngine's PEG Ratio has ranged from 0.17 to 63.58. According to the industry distribution chart, PharmaEngine ranks #67 out of 94 companies in the Biotechnology industry, placing it in the top 71.3%.
Is PharmaEngine's PEG Ratio too high?
PharmaEngine's current PEG Ratio of 3.87 is 114% above median its 10-year median of 1.81. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 63.58. The Biotechnology industry median PEG Ratio is 1.94. PharmaEngine's value of 3.87 is 99.5% above this industry median. Based on the distribution chart, PharmaEngine ranks #67 out of 94 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #67 out of 94 companies for PEG Ratio. This places PharmaEngine in the lower half of its industry. The industry median PEG Ratio is 1.94. PharmaEngine's value of 3.87 is 99.5% above this benchmark. Historically, PharmaEngine's own PEG Ratio has ranged from 0.17 to 63.58 over the past decade. While the company's 10-year median is 1.81 vs. the industry median of 1.94, PharmaEngine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.94, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEngine's current PEG Ratio of 3.87 is 99.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on PharmaEngine and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEngine's current PEG Ratio is 3.87, which is 114% above median its own 10-year median of 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.42, compared to a current price of NT$64.50 — trading 44.1% below its estimated fair value. The current PEG Ratio is 3.87, which is 114% above median its 10-year median of 1.81 and 99.5% above the Biotechnology industry median of 1.94. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current PEG Ratio is 3.87 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$64.50 is trading 44.1% below its estimated GF Value™ of NT$115.42.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
PEG Ratio: 3.87 (114% above median its 10-year median of 1.81)
GF Value™: NT$115.42 vs. price of NT$64.50 (44.1% below fair value)
Industry Position: 99.5% above the Biotechnology median (#67 of 94)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score
Get the complete analysis for ROCO:4162
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
